Recent Updates
Recently added Catalysts
RARE

Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease

Wednesday, December 9, 2020 1 min read
Key Takeaway: Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease

Full Press Release Details

Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease.
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Dec 9, 2020